- Trustees, Management & Advisers
Trustees, Management & Advisers
Trustees
- Professor Paul Lorigan (chairman; professor of medical oncology, University of Manchester)
- Dr Katharine Acland (consultant dermatologist, Guy’s & St Thomas’ NHS Trust)
- Professor Martin Cook (consultant histopathologist, Royal Surrey County Hospital)
- Dr Pippa Corrie (consultant medical oncologist, Cambridge University Hospitals NHS Foundation Trust)
- Dr Mark Harries (consultant medical oncologist, Guy’s and St Thomas’ NHS Foundation Trust)
- Professor Richard Marais (scientist, CRUK Manchester Institute)
- Dr Jerry Marsden (consultant dermatologist, Queen Elizabeth Hospital Birmingham)
- Dr Paul Nathan (consultant medical oncologist, Mount Vernon Cancer Centre)
- Mr Howard Peach (consultant plastic and reconstructive surgeon, Leeds Teaching Hospitals NHS Trust)
- Professor Barry Powell (consultant plastic and reconstructive surgeon, St George’s Healthcare NHS Trust)
Management and Advisers
- Chief Executive Officer: Simon Rodwell
- Financial Adviser: Stephen Sandys
NHS confirms revised stopping and retreatment rules for immunotherapy patients
NHS England has confirmed its financial support for the re-starting of anti PD-1 treatments for patients with melanoma. Clinicians will now be able to halt treatment after two years confident that funding for the drugs will be available if the disease progresses and the treatment needs to be resumed in the future.
READ MOREMelanoma Focus launches Sentinel Node Biopsy Guideline
New guidance on this surgical procedure and related issues, including the need for completion lymphadenectomy, has been released by a 70-strong group of clinicians, nurses & patient representatives who met in May 2018 to discuss and reach consensus on this controversial topic. Advances in melanoma treatments and the findings of recent trials prompted this review.
READ MOREFirst safe and effective adjuvant therapy for melanoma is now available on the NHS
Patients and clinicians have welcomed the announcement of a new adjuvant therapy drug combination. ‘This is the first treatment to be made available that shows a significant reduction in the risk of dying from the recurrence of melanoma after surgery,’ says Melanoma Focus Chairman Professor Paul Lorigan. ‘This milestone will transform outcomes for many patients’.
READ MOREASICS Manchester Marathon 2019
7 April 2018 – Run with Melanoma Focus to help raise money for research into the causes and treatment of melanoma.
READ MORE
100 Miles in May Challenge Event
100 Miles in May is a challenge event that anyone can take part in whether they are a cyclist, runner, walker or swimmer. Join the challenge and help raise money in the fight against melanoma.
READ MORE